Webb, D.J. and Walker, A. (2007) Value-based pricing of drugs in the UK. Lancet, 369(9571), pp. 1415-1416.
Full text not currently available from Enlighten.
Publisher's URL: http://www.thelancet.com/journals/lancet/issue/current?tab=past
Abstract
The Pharmaceutical Price Regulatory Scheme (PPRS), launched over 50 years ago, was designed to secure safe and effective drugs for the UK National Health Service (NHS) at reasonable prices, and to promote a strong and profitable pharmaceutical industry able to develop new and improved drugs.1 On Feb 20, 2007, the Office of Fair Trading (OFT), the UK's independent competition and consumer protection authority, recommended to the UK Government that the PPRS should be radically reformed to deliver better value for money from the NHS drug budget and to focus business investment on drugs that have the greatest benefits for patients.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Walker, Dr Andrew |
| Authors: | Webb, D.J., and Walker, A. |
| Subjects: | R Medicine > R Medicine (General) |
| College/School: | College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre ?? 20206000 ?? |
| Journal Name: | Lancet |
| Publisher: | The Lancet Publishing Group |
| ISSN: | 0140-6736 |
| ISSN (Online): | 1474-547X |
| Published Online: | 28 April 2007 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details